Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
October 20, 2021 07:00 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...